Exhibit 99.1



FOR IMMEDIATE RELEASE:

               AMERICAN BIO MEDICA PURCHASES HEADQUARTERS FACILITY
   -- Acquisition Consolidates Out-Of-Pocket Expenses, Streamlines Overhead --

KINDERHOOK, NY, December 12, 2001 - American Bio Medica Corporation (NASDAQ:
ABMC) today announced that it has purchased its headquarters facility in
Kinderhook, New York, from Avoba Inc. for $950,000. The deal will significantly
reduce ABMC's yearly facilities expenses and enable the company to maintain and
grow its operations in Columbia County, New York.

Included in the purchase are ABMC's headquarters facility, its contents, and 107
acres of property. The Hudson River Bank & Trust, the New York Business
Development Corporation, and the Columbia Economic Development Corporation
provided financing for the deal. ABMC provided $230,000 in equity. The company
also noted that it expects to receive local tax benefits, and plans to subdivide
and sell 80 acres of property to off-set acquisition costs. ABMC also noted that
the purchase price of the facility was $350,000 lower than the original asking
price.

The company previously paid $120,000 per year in rent for the facility. The new
mortgage package will total approximately $70,000 in annual expenses,
representing a net decrease in cost of annual occupation of $50,000.

"We are pleased to make this purchase, not only because it reduces our annual
operating expenses and strengthens our in-house production capabilities, but it
represents a commitment from ABMC and state and local government to help our
business grow in this community," remarked Keith Palmer, chief financial officer
for ABMC.

About American Bio Medica Corporation
American Bio Medica Corporation develops, manufactures and markets inexpensive,
accurate, on-site drugs-of-abuse diagnostic kits, sprays and support services
worldwide. The company's global distributors target the workplace, physicians,
corrections, clinical, and educational markets. ABMC's Rapid Drug Screen(R) and
OralStat-6(TM) test for the presence of absence of drugs of abuse in urine and
saliva, respectively, while its Drug Detector(TM) identifies minute traces of
illegal drugs on surfaces. ABMC was recently listed among the top ten
biotechnology companies on the Deloitte & Touche 2001 Technology Fast 500, a
ranking of the fastest growing companies in North America.

Forward-looking statements in this release are made pursuant to the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements involve risk and
uncertainties, including without limitation, continued acceptance of the
Company's products, increased levels of competition for the Company, new
products and technological changes, intellectual property rights and other risks
detailed from time to time in the Company's periodic reports filed with the
Securities and Exchange Commission.

                                      # # #

                                        5